EE200200496A - 4-amino-6,7-dimetoksü-2-(5-metaansulfoonamido-1,2,3,4-tetrahüdroisokinool-2-üül)-5 -(2-püridüül)kinasoliinmesülaat ja selle polümorfid - Google Patents

4-amino-6,7-dimetoksü-2-(5-metaansulfoonamido-1,2,3,4-tetrahüdroisokinool-2-üül)-5 -(2-püridüül)kinasoliinmesülaat ja selle polümorfid

Info

Publication number
EE200200496A
EE200200496A EEP200200496A EEP200200496A EE200200496A EE 200200496 A EE200200496 A EE 200200496A EE P200200496 A EEP200200496 A EE P200200496A EE P200200496 A EEP200200496 A EE P200200496A EE 200200496 A EE200200496 A EE 200200496A
Authority
EE
Estonia
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
polymorphs
dimethoxy
pyridyl
Prior art date
Application number
EEP200200496A
Other languages
English (en)
Inventor
Ann Basford Patricia
Blaise Hodgson Paul
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005200A external-priority patent/GB0005200D0/en
Priority claimed from GB0015900A external-priority patent/GB0015900D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200200496A publication Critical patent/EE200200496A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200200496A 2000-03-03 2001-02-23 4-amino-6,7-dimetoksü-2-(5-metaansulfoonamido-1,2,3,4-tetrahüdroisokinool-2-üül)-5 -(2-püridüül)kinasoliinmesülaat ja selle polümorfid EE200200496A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005200A GB0005200D0 (en) 2000-03-03 2000-03-03 New salt form
GB0015900A GB0015900D0 (en) 2000-06-28 2000-06-28 New salt form
PCT/IB2001/000244 WO2001064672A1 (en) 2000-03-03 2001-02-23 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs

Publications (1)

Publication Number Publication Date
EE200200496A true EE200200496A (et) 2004-02-16

Family

ID=26243792

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200496A EE200200496A (et) 2000-03-03 2001-02-23 4-amino-6,7-dimetoksü-2-(5-metaansulfoonamido-1,2,3,4-tetrahüdroisokinool-2-üül)-5 -(2-püridüül)kinasoliinmesülaat ja selle polümorfid

Country Status (40)

Country Link
US (1) US6683085B2 (et)
EP (1) EP1268468B1 (et)
JP (1) JP3857919B2 (et)
KR (1) KR100496089B1 (et)
CN (1) CN1214029C (et)
AP (1) AP2002002611A0 (et)
AR (1) AR029482A1 (et)
AT (1) ATE253570T1 (et)
AU (1) AU779118B2 (et)
BG (1) BG106869A (et)
BR (1) BR0108910A (et)
CA (1) CA2398963C (et)
CR (1) CR6731A (et)
CZ (1) CZ20022858A3 (et)
DE (1) DE60101157T2 (et)
DK (1) DK1268468T3 (et)
EA (1) EA004748B1 (et)
EE (1) EE200200496A (et)
ES (1) ES2208565T3 (et)
GE (1) GEP20043364B (et)
HK (1) HK1053655A1 (et)
HN (1) HN2001000036A (et)
HR (1) HRP20020718A2 (et)
HU (1) HUP0300006A3 (et)
IL (1) IL150634A0 (et)
IS (1) IS6441A (et)
MA (1) MA26876A1 (et)
MX (1) MXPA02008665A (et)
NO (1) NO20024195L (et)
NZ (1) NZ519672A (et)
OA (1) OA12186A (et)
PE (1) PE20011225A1 (et)
PL (1) PL365070A1 (et)
PT (1) PT1268468E (et)
SI (1) SI1268468T1 (et)
SK (1) SK12282002A3 (et)
TN (1) TNSN01034A1 (et)
TR (1) TR200302130T4 (et)
UA (1) UA72311C2 (et)
WO (1) WO2001064672A1 (et)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
DE10223913A1 (de) * 2002-05-29 2003-12-11 Bayer Cropscience Ag Verfahren zur Herstellung spezifischer Kristallmodifikationen polymorpher Substanzen
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914114A (en) 1984-05-28 1990-04-03 Merck Patent Gesellschaft Mit Breschrankter Haftung 3-[4-(4-phenyl-1,2,3,6-tetrahydro-1-pyridyl)butyl]-5-hydroxy-indole methanesulfonate having sedating and anti-parkinsonism properties
EP0281608B1 (de) * 1986-09-16 1990-07-11 MERCK PATENT GmbH Hydroxyindolderivat
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CZ20022858A3 (cs) 2003-09-17
WO2001064672A1 (en) 2001-09-07
MA26876A1 (fr) 2004-12-20
PE20011225A1 (es) 2001-12-08
EA004748B1 (ru) 2004-08-26
IS6441A (is) 2002-06-25
HK1053655A1 (en) 2003-10-31
HN2001000036A (es) 2001-07-09
HRP20020718A2 (en) 2004-02-29
HUP0300006A3 (en) 2006-01-30
US20020010188A1 (en) 2002-01-24
AP2002002611A0 (en) 2002-09-30
CN1214029C (zh) 2005-08-10
BR0108910A (pt) 2002-12-24
CR6731A (es) 2004-03-11
NO20024195D0 (no) 2002-09-03
CN1432010A (zh) 2003-07-23
AU779118B2 (en) 2005-01-06
DE60101157T2 (de) 2004-09-02
UA72311C2 (uk) 2005-02-15
EP1268468A1 (en) 2003-01-02
KR100496089B1 (ko) 2005-06-17
TNSN01034A1 (fr) 2005-11-10
SI1268468T1 (en) 2004-04-30
US6683085B2 (en) 2004-01-27
EP1268468B1 (en) 2003-11-05
ATE253570T1 (de) 2003-11-15
CA2398963C (en) 2006-10-24
PL365070A1 (en) 2004-12-27
ES2208565T3 (es) 2004-06-16
TR200302130T4 (tr) 2004-01-21
AU3588801A (en) 2001-09-12
DE60101157D1 (de) 2003-12-11
PT1268468E (pt) 2004-01-30
SK12282002A3 (sk) 2003-10-07
NZ519672A (en) 2004-06-25
MXPA02008665A (es) 2003-02-24
CA2398963A1 (en) 2001-09-07
JP2003525289A (ja) 2003-08-26
GEP20043364B (en) 2004-03-10
JP3857919B2 (ja) 2006-12-13
AR029482A1 (es) 2003-07-02
EA200200826A1 (ru) 2003-02-27
NO20024195L (no) 2002-09-03
BG106869A (bg) 2002-12-29
IL150634A0 (en) 2003-02-12
OA12186A (en) 2006-05-09
HUP0300006A2 (en) 2003-05-28
DK1268468T3 (da) 2004-02-09
KR20020080463A (ko) 2002-10-23

Similar Documents

Publication Publication Date Title
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
IS7227A (is) Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini
DE60234376D1 (de) 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
IS6968A (is) Nýir týrósínkínasa tálmar
DE60217669D1 (de) Substitutierte pyrazinone, pyridine und pyrimidine als corticotropin-releasing-factor liganden
NO20024308L (no) Arylsubstituerte pyridiner, pyrimidiner og triaziner og deres anvendelse
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
NO20030795L (no) Kinazolinderivater
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
ATE253561T1 (de) 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
EE200200496A (et) 4-amino-6,7-dimetoksü-2-(5-metaansulfoonamido-1,2,3,4-tetrahüdroisokinool-2-üül)-5 -(2-püridüül)kinasoliinmesülaat ja selle polümorfid
DK1335906T3 (da) Pyrimidinderivater og anvendelse deraf som neuropeptid Y-receptorligander
EE200300491A (et) 6-asendis asendatud indolinoonid ja nende kasutamine kinaas-inhibiitoritena
NO20040990L (no) Andvendelse av LH i kontrollert ovariehyperstimulering.
NO20041520L (no) Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.
UA5368S (uk) Навіс для вікон, балконів і терас
DK1226136T3 (da) Tyrosinkinaseinhibitor